PTCA restenosis    Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study J Am Coll Cardiol (2004);44:1386-92 R. Waksman, et al. Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from the sirius trial J Am Coll Cardiol (2004);43:1959-63 S. Sonoda, et al. Clinical and angiographic predictors of restenosis after percutaneous coronary intervention: insights from the Prevention of Restenosis With Tranilast and Its Outcomes (PRESTO) trial Circulation (2004);109:2727-31 M. Singh, et al. Pre-procedural plasma levels of C-reactive protein and interleukin-6 do not predict late coronary angiographic restenosis after elective stenting Eur Heart J (2004);25:1029-35 A. Segev, et al. Heme oxygenase-1 genotype and restenosis after balloon angioplasty: a novel vascular protective factor J Am Coll Cardiol (2004);43:950-7 M. Schillinger, et al. Blockade of vascular endothelial growth factor suppresses experimental restenosis after intraluminal injury by inhibiting recruitment of monocyte lineage cells Circulation (2004);110:2444-52 K. Ohtani, et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial Circulation (2004);109:476-80 V. Mathew, et al. Post-sirolimus-eluting stent restenosis treated with repeat percutaneous intervention: late angiographic and clinical outcomes Circulation (2004);109:2500-2 P. A. Lemos, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study Circulation (2004);109:1366-70 P. A. Lemos, et al. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial Circulation (2004);110:790-5 J. Hausleiter, et al. Can we afford to eliminate restenosis? Can we afford not to? J Am Coll Cardiol (2004);43:513-8 D. Greenberg, et al. Myocardial perfusion imaging following percutaneous coronary intervention: the importance of restenosis, disease progression, and directed reintervention J Am Coll Cardiol (2004);43:328-36 K. N. Giedd and S. R. Bergmann Contribution of early lumen loss after balloon angioplasty for in-stent restenosis to lumen loss at follow-up Catheter Cardiovasc Interv (2004);63:52-6 K. Fujii, et al. Evaluation of the effect of oral verapamil on clinical outcome and angiographic restenosis after percutaneous coronary intervention: the randomized, double-blind, placebo-controlled, multicenter Verapamil Slow-Release for Prevention of Cardiovascular Even J Am Coll Cardiol (2004);43:2160-5 H. P. Bestehorn, et al.